A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma

Administration of NGR-TNF, a tumor vessel-targeting and tumor necrosis factor α TNFα) peptide conjugate, with immunotherapy has been shown to inhibit tumor growth in mice. Thus, we planned a Phase I pilot clinical trial to assess safety, immune and clinical response of this combination treatment for...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncoimmunology
Egile Nagusiak: Parmiani, Giorgio, Pilla, Lorenzo, Corti, Angelo, Doglioni, Claudio, Cimminiello, Carolina, Bellone, Matteo, Parolini, Danilo, Russo, Vincenzo, Capocefalo, Filippo, Maccalli, Cristina
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2014
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4368149/
https://ncbi.nlm.nih.gov/pubmed/25941591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/21624011.2014.963406
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak